Hanx Biopharmaceuticals repurchases HKD 1.07 million of H-shares; treasury stock climbs to 0.68 % of total issued capital

Bulletin Express06-02

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 02 June 2026 under its existing mandate approved on 12 February 2026.

Key transaction details • Shares repurchased: 40,200 H-shares, equivalent to 0.03 % of the company’s issued share capital (excluding treasury shares) prior to the transaction. • Price range: HKD 25.34–28.42 per share, with a volume-weighted average of HKD 26.57. • Aggregate consideration: HKD 1.07 million, settled entirely in cash. • Purpose: All repurchased shares were retained as treasury stock; none were cancelled.

Capital structure impact (post-transaction, 02 June 2026) • Issued shares outstanding (excluding treasury): 135.29 million. • Treasury shares on hand: 0.92 million, equal to 0.68 % of the company’s total issued shares of 136.22 million. • Cumulative repurchases under the current mandate: 924,900 shares, representing 0.679 % of the issued share base as at the mandate date.

Regulatory considerations • The repurchase complied with Hong Kong Main Board Rule 10.06 and related provisions. • A 30-day moratorium on new share issues or the disposal of treasury shares extends through 02 July 2026.

No shares have been earmarked for cancellation, leaving overall share count unchanged at 136.22 million, while market float has been marginally reduced by the transferred shares now held in treasury.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114495285?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114495285","market":"us","top_or_hot":-1,"title":"Hanx Biopharmaceuticals repurchases HKD 1.07 million of H-shares; treasury stock climbs to 0.68 % of total issued capital","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 02 June 2026 under its existing mandate approved on 12 February 2026.</p>\n<p>Key transaction details  \n• Shares repurchased: 40,200 H-shares, equivalent to 0.03 % of the company’s issued share capital (excluding treasury shares) prior to the transaction.  \n• Price range: HKD 25.34–28.42 per share, with a volume-weighted average of HKD 26.57.  \n• Aggregate consideration: HKD 1.07 million, settled entirely in cash.  \n• Purpose: All repurchased shares were retained as treasury stock; none were cancelled.</p>\n<p>Capital structure impact (post-transaction, 02 June 2026)  \n• Issued shares outstanding (excluding treasury): 135.29 million.  \n• Treasury shares on hand: 0.92 million, equal to 0.68 % of the company’s total issued shares of 136.22 million.  \n• Cumulative repurchases under the current mandate: 924,900 shares, representing 0.679 % of the issued share base as at the mandate date.</p>\n<p>Regulatory considerations  \n• The repurchase complied with Hong Kong Main Board Rule 10.06 and related provisions.  \n• A 30-day moratorium on new share issues or the disposal of treasury shares extends through 02 July 2026.</p>\n<p>No shares have been earmarked for cancellation, leaving overall share count unchanged at 136.22 million, while market float has been marginally reduced by the transferred shares now held in treasury.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals repurchases HKD 1.07 million of H-shares; treasury stock climbs to 0.68 % of total issued capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals repurchases HKD 1.07 million of H-shares; treasury stock climbs to 0.68 % of total issued capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-02 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 02 June 2026 under its existing mandate approved on 12 February 2026.</p>\n<p>Key transaction details  \n• Shares repurchased: 40,200 H-shares, equivalent to 0.03 % of the company’s issued share capital (excluding treasury shares) prior to the transaction.  \n• Price range: HKD 25.34–28.42 per share, with a volume-weighted average of HKD 26.57.  \n• Aggregate consideration: HKD 1.07 million, settled entirely in cash.  \n• Purpose: All repurchased shares were retained as treasury stock; none were cancelled.</p>\n<p>Capital structure impact (post-transaction, 02 June 2026)  \n• Issued shares outstanding (excluding treasury): 135.29 million.  \n• Treasury shares on hand: 0.92 million, equal to 0.68 % of the company’s total issued shares of 136.22 million.  \n• Cumulative repurchases under the current mandate: 924,900 shares, representing 0.679 % of the issued share base as at the mandate date.</p>\n<p>Regulatory considerations  \n• The repurchase complied with Hong Kong Main Board Rule 10.06 and related provisions.  \n• A 30-day moratorium on new share issues or the disposal of treasury shares extends through 02 July 2026.</p>\n<p>No shares have been earmarked for cancellation, leaving overall share count unchanged at 136.22 million, while market float has been marginally reduced by the transferred shares now held in treasury.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1114495285","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114495285","pubTimestamp":1780400611,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 02 June 2026 under its existing mandate approved on 12 February 2026. Key transaction details   • Shares repurchased:...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克思生物制药回购107万港元H股；库存股占已发行资本总额的0.68%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 02 June 2026 under its existing mandate approved on 12 February 2026.\nKey transaction details  \n• Shares repurchased: 40,200 H-shares, equivalent to 0.03 % of the company’s issued share capital (excluding treasury shares) prior to the transaction.  \n• Price range: HKD 25.34–28.42 per share, with a volume-weighted average of HKD 26.57.  \n• Aggregate consideration: HKD 1.07 million, settled entirely in cash.  \n• Purpose: All repurchased shares were retained as treasury stock; none were cancelled.\nCapital structure impact (post-transaction, 02 June 2026)  \n• Issued shares outstanding (excluding treasury): 135.29 million.  \n• Treasury shares on hand: 0.92 million, equal to 0.68 % of the company’s total issued shares of 136.22 million.  \n• Cumulative repurchases under the current mandate: 924,900 shares, representing 0.679 % of the issued share base as at the mandate date.\nRegulatory considerations  \n• The repurchase complied with Hong Kong Main Board Rule 10.06 and related provisions.  \n• A 30-day moratorium on new share issues or the disposal of treasury shares extends through 02 July 2026.\nNo shares have been earmarked for cancellation, leaving overall share count unchanged at 136.22 million, while market float has been marginally reduced by the transferred shares now held in treasury.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114495285","isCrawlerRequest":true}